We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 2 of 4 for:    st. jude severe combined immunodeficiency

Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants (LVXSCID-ND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01512888
Recruitment Status : Recruiting
First Posted : January 19, 2012
Last Update Posted : November 6, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
SCID-X1 is a genetic disorder of blood cells caused by DNA changes in a gene that is required for the normal development of the human immune system. The purpose of this study is to determine if a new method, called lentiviral gene transfer, can be used to treat SCID-X1. This method involves transferring a normal copy of the common gamma chain gene into the participant's bone marrow stem cells. The investigators want to determine if the procedure is safe, whether it can be done according to the methods they have developed, and whether the procedure will provide a normal immune system for the patient. It is hoped that this type of gene transfer may offer a new way to treat children with SCID-X1 that do not have a brother or sister who can be used as a donor for stem cell transplantation.

Condition or disease Intervention/treatment Phase
Severe Combined Immunodeficiency Disease, X-linked Genetic: CL20-4i-EF/a-hyc-OPT Drug: Busulfan Device: CliniMacs Phase 1 Phase 2

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Feasibility Study of Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells
Actual Study Start Date : August 17, 2016
Estimated Primary Completion Date : August 2025
Estimated Study Completion Date : August 2034

Arms and Interventions

Arm Intervention/treatment
Experimental: Treatment
Participants will undergo a bone marrow harvest in the operating room to obtain bone marrow cells. Cells will be isolated and purified utilizing the CliniMacs device. These cells will undergo vector transduction with the lentiviral vector that contains a normal copy of the γc gene gene (CL20-4i-EF/a-hyc-OPT) and then the transduced cells will be reinfused back into the patient. Participants will receive a conditioning regimen of busulfan 3 days prior and 2 days prior to infusion of vector-corrected cells.intervention: CL20-4i-EF/a-hyc-OPT
Genetic: CL20-4i-EF/a-hyc-OPT
Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human γc gene.
Other Names:
  • self inactivating lentiviral vector
  • IND 14570
Drug: Busulfan
Given intravenously (IV).
Other Names:
  • Busulfex®
  • Myleran®
Device: CliniMacs
Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.

Outcome Measures

Primary Outcome Measures :
  1. Number of patients with adequate cell collection and processing [ Time Frame: Day 0 ]
    The number of patients who underwent no more than two bone marrow harvests and cryopreservation of at least 1.0 million cells/kg following vector transduction.

  2. Number of patients with adequate neutrophil count recovery after busulfan conditioning [ Time Frame: Day 42 post gene transfer ]
    Adequate recovery is defined as absolute neutrophil count (ANC) >500 cells/μl by day +42 unless the patient is neutropenic prior to busulfan administration.

  3. Number of patients without Grade 4 adverse event (AE) [ Time Frame: 42 days post gene transfer ]
    The number of patients experiencing no directly related grade 4 or greater adverse event.

  4. Number of patients with successful reconstitution [ Time Frame: 42 days post gene transfer ]
    Reconstitution with transduced cells defined as detection of vector-marked peripheral blood cells by real time PCR at or above 0.02% VCN in total WBC.

  5. Number of patients with treatment failure [ Time Frame: 42 days post gene transfer ]
    Treatment failure will be defined as lack of adequate cell collection and processing, lack of neutrophil count recovery by day +42, occurrence of grade 4 or greater toxicities by day +42, and/or lack of detection of >0.02% transduced cells in peripheral blood by day +42 post gene transfer.

Other Outcome Measures:
  1. Pharmacokinetic (PK) variables of busulfan [ Time Frame: Days -2 and -1 prior to therapy ]
    Blood collections for pharmacokinetic sampling will be performed with dose 1 and used to determine dose modifications for dose 2, if needed. The specific times for blood collects will be institution specific. Summary statistics will be reported.

  2. Number of patients who achieve the desired therapeutic busulfan AUC [ Time Frame: Day 0 ]
    The efficacy of busulfan dose-targeting with busulfan administration every 24 hours for a total of 2 doses in order to achieve a cumulative busulfan AUC of 22 mg*hr/L will be evaluated. The number of patients who achieve the desired therapeutic busulfan AUC will be reported

  3. B-cell function evaluated by Immune response [ Time Frame: 52 weeks post gene transfer ]
    Evaluation may include γc expression in circulating B-cells, measurement of serum IgG, IgA, and IgM concentration, measurement of antibody responses to vaccination, evaluation of IgG production after cessation of intravenous gamma globulin therapy in patients with clinical indications to discontinue IVIG. Summary statistics will be reported.

  4. Number of NK cells [ Time Frame: 52 weeks post gene transfer ]
    Evaluation will include flow cytometry evaluation of NK cell numbers. Summary statistics will be reported.

  5. Vector copy number by location of vector-integration sites in sorted blood cells [ Time Frame: up to 10 years post gene transfer ]
    Sorted T-cells, B-cells, NK cells, granulocytes and monocytes will be evaluated for vector copy number. Studies on sorted cells will also include deep sequencing with an automated sequencer to characterize insertion sites, and expression array analysis of T-cell clones to assay for gene expression alterations within 100 kb of the insertion sites. Summary statistics will be reported.

  6. Event-free survival (EFS) [ Time Frame: from baseline up to 10 years post gene transfer ]
  7. Overall survival (OS) [ Time Frame: up to 10 years post gene transfer ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 24 Months   (Child)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No

Inclusion Criteria:

* Treatment Eligibility Criteria:

  • Age <2 years at the time of enrollment.
  • No prior therapy with allogeneic stem cell transplantation.
  • A clinical diagnosis of SCID-X1 documented in the medical record.
  • A proven mutation in the common gamma chain gene as defined by direct sequencing of patient DNA.
  • Age > 2 months to < 1 year of age at the time of busulfan administration.
  • Less than 300 CD3+ T-cells by flow cytometry or higher if evidence of maternal engraftment as supported by peripheral blood FISH analysis for XY and XX.
  • Lymphocyte proliferation to phytohemagglutinin (PHA) <10% of the lower limit of normal for the laboratory.

Treatment Exclusion Criteria:

  • Availability of a HLA matched sibling for allogeneic transplantation
  • Prior therapy with allogeneic stem cell transplantation
  • Positive for HIV infection by genome PCR
  • Presence of a medical condition indicating that survival will be less than 16 weeks such as the requirement for mechanical ventilation, severe failure of a major organ system, or evidence of a serious, progressive infection that is refractory to medical therapy.
  • The presence of any medical contraindications to general anesthesia and bone marrow harvest by aspiration
  • A social situation indicating that the family may not be able to comply with protocol procedures and recommended medical care.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01512888

Contact: Stephen Gottschalk, MD 901-595-2166 stephen.gottschalk@stjude.org
Contact: Ewelina Mamcarz, MD 901-595-8343 ewelina.mamcarz@stjude.org

United States, California
University of California-San Francisco Recruiting
San Francisco, California, United States, 94158
Contact: Mort Cowan, MD    415-476-2656    mort-cowan@ucsf.edu   
Principal Investigator: Mort Cowan, MD         
Sub-Investigator: Jennifer Puck, MD         
United States, Tennessee
St. Jude Children's Research Hospital Recruiting
Memphis, Tennessee, United States, 38105
Contact: Stephen Gottschalk, MD    901-595-2166    stephen.gottschalk@stjude.org   
Principal Investigator: Stephen Gottschalk, MD         
Sub-Investigator: Ewelina Mamcarz, MD         
United States, Washington
Seattle Children's Research Institute Not yet recruiting
Seattle, Washington, United States, 98101
Contact: Aleksandra Petrovic, MD    206-987-7450    aleksandra.petrovic@seattlechildrens.org   
Principal Investigator: Aleksandra Petrovic, MD         
Sub-Investigator: David J. Rawlings, MD         
Sponsors and Collaborators
St. Jude Children's Research Hospital
National Heart, Lung, and Blood Institute (NHLBI)
Assisi Foundation
Principal Investigator: Stephen Gottschalk, MD St. Jude Children's Research Hospital
More Information

Additional Information:
Responsible Party: St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier: NCT01512888     History of Changes
Other Study ID Numbers: LVXSCID-ND
P01HL053749 ( U.S. NIH Grant/Contract )
First Posted: January 19, 2012    Key Record Dates
Last Update Posted: November 6, 2017
Last Verified: November 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No

Keywords provided by St. Jude Children's Research Hospital:
X-linked SCID
gene therapy

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Severe Combined Immunodeficiency
X-Linked Combined Immunodeficiency Diseases
Immune System Diseases
Infant, Newborn, Diseases
DNA Repair-Deficiency Disorders
Metabolic Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Alkylating
Antineoplastic Agents
Myeloablative Agonists